COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Hypnosis for Smoking Relapse Prevention (HypnoRelapse)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00770380
Recruitment Status : Completed
First Posted : October 10, 2008
Last Update Posted : October 31, 2017
Information provided by (Responsible Party):
Timothy Carmody, University of California, San Francisco

Brief Summary:
A majority of smokers who quit return to smoking within three months of their quit date. This study is a randomized trial to investigate the effectiveness of hypnosis versus behavioural counseling to promote maintenance of abstinence or relapse prevention in quitting smokers. The hypothesis is that hypnosis will be at least as effective as behavioral counseling in preventing relapse to smoking in smokers who are able to quit for at least three days.

Condition or disease Intervention/treatment Phase
Smoking Behavioral: behavioral relapse prevention counseling Other: hypnosis for relapse prevention Not Applicable

Detailed Description:

We will enroll 520 current smokers in the study. All subjects will participate in an initial smoking cessation intervention involving brief counseling and nicotine replacement therapy. Participants who are able to achieve at least 3 consecutive days of abstinence will be randomized to one of two relapse prevention interventions. The participants in Study Arm 1 will receive a hypnosis intervention designed to facilitate relapse prevention. Participants in Study Arm 2 will participate in empirically-supported behavior relapse prevention counseling, utilizing the National Cancer Institute's Forever Free materials. Both interventions will be conducted in two 60-minute individual sessions scheduled one week apart in addition to counseling phone calls on their quit date and after relapse prevention treatment.

Outcomes for the two study arms will be compared by assessing biochemically-validated point-prevalence smoking status at 9 weeks(end of treatment), 26 weeks and 52 weeks. Hypnosis for relapse prevention is designed to sustain the ex-smokers commitment to remain abstinent, to provide a review of behavioral skills to resist the temptations to smoke, and to encourage attempts to quit again if relapse occurs.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 139 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Hypnosis for Smoking Relapse Prevention
Study Start Date : June 2007
Actual Primary Completion Date : May 2011
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Smoking

Arm Intervention/treatment
Experimental: Hypnosis for relapse prevention
The hypnosis intervention was conducted in two face-to-face visits with hypnosis recorded for home practice. Learning, practicing, and employing hypnotic skills in resisting the urge to smoke are core components of this intervention.
Other: hypnosis for relapse prevention
Hypnosis for relapse prevention conducted in two one-hour sessions
Other Name: hypnotherapy

Active Comparator: Behavioral relapse prevention counseling
In the behavioral relapse prevention counseling, participants were taught coping strategies for resisting the urge to smoke. This intervention focused on relapse prevention (i.e., maintenance stage of change) and was based on the theoretical concepts and treatment procedures advocated by Marlatt and Gordon and recent smoking relapse data.
Behavioral: behavioral relapse prevention counseling
Behavioral relapse prevention counseling conducted in two one-hour sessions
Other Name: relapse prevention

Primary Outcome Measures :
  1. Point prevalence smoking status at 9, 26 and 52 weeks [ Time Frame: one year ]
    Point prevalence smoking status during past 7 days

Secondary Outcome Measures :
  1. continuous quitting as measured by reported non-smoking at 9, 26 and 52 weeks continuously [ Time Frame: one year ]
    Reported continuous abstinence from smoking

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • currently smoking at least 5/cigarettes per day during the past week
  • willingness to participate and give informed consent
  • aged 18 and above

Exclusion Criteria:

  • contraindications to nicotine replacement
  • pregnancy, lactation
  • unstable psychiatric disorders
  • current (last 3 months)substance use disorder
  • terminal illness
  • current use of smoking cessation medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00770380

Layout table for location information
United States, California
Veterans Affairs Medical Center, 4150 Clement Street
San Francisco, California, United States, 94121
Sponsors and Collaborators
University of California, San Francisco
Layout table for investigator information
Principal Investigator: Timothy P Carmody, PhD University of California, San Francisco
Layout table for additonal information
Responsible Party: Timothy Carmody, Health Sciences Clinical Professor, University of California, San Francisco Identifier: NCT00770380    
Other Study ID Numbers: 16RT-0074
18109-557309 ( Other Identifier: TRDRP )
First Posted: October 10, 2008    Key Record Dates
Last Update Posted: October 31, 2017
Last Verified: October 2017
Keywords provided by Timothy Carmody, University of California, San Francisco:
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease Attributes
Pathologic Processes